Serum amyloid A protein glycosaminoglycan binding site (SAA-GAG binding site)

Serum amyloid A (SAA) is an acute-phase reactant protein produced by the liver during chronic inflammation that can misfold and aggregate into insoluble amyloid fibrils, leading to systemic AA amyloidosis (Nienhuis et al., 2016). Glycosaminoglycans (GAGs), particularly heparan sulfate proteoglycans, are essential co-factors that bind to specific basic amino acid clusters on the SAA protein, promoting fibril nucleation and providing structural stability to the resulting deposits. The SAA-GAG binding site is a critical therapeutic target because this interaction protects amyloid fibrils from proteolytic degradation and facilitates their accumulation in vital organs such as the kidneys, liver, and spleen (Noborn et al., 2012). Therapeutic strategies, such as the use of GAG mimetics like eprodisate, aim to competitively occupy these binding sites to inhibit fibril formation and promote the clearance of existing deposits. By disrupting the structural integrity of the fibrils, these interventions seek to preserve organ function and mitigate the progression of inflammatory amyloidosis (Dember et al., 2007).

Other names

Serum amyloid A-heparan sulfate binding siteSAA heparin-binding domainAA amyloid fibril GAG binding siteSerum amyloid A-glycosaminoglycan interaction site

Eprodisate acts as a small-molecule negative-charge mimetic of heparan sulfate, competitively binding to the glycosaminoglycan (GAG) binding sites on serum amyloid A (SAA) subunits. This prevents the interaction between SAA and endogenous GAGs, which is necessary for the stabilization, deposition, and persistence of amyloid fibrils in tissues (Dember et al., 2007).